top of page

Molecular testing

What is molecular testing? And why is it important?

Molecular testing, also referred to as Biomarker testing or Genomic sequencing, can open the door to personalized treatment options and clinical trials. Molecular testing involves examining the genetic material, usually taken from a tumor biopsy, to identify mutations and alterations that are known to be associated with cholangiocarcinoma. Knowing which biomarkers you have (or don't have) can help doctors tailor a specific treatment plan to each person's unique genetic makeup.  

Biomarkers Matter (English)

Biomarkers Matter (French)

*Video content from cholangiocarcinoma.org 

Get molecular testing

See under "For Patients" or "For Professionals" for more details

You may be eligible for molecular testing through clinical trials.

Below are clinical trials in Canada that offer molecular testing related to cholangiocarcinoma. 

Sponsored by University Health Network and in collaboration with Princess Margaret Cancer Centre 

Contact: CGP@uhn.ca

Sponsored by Dr. George Zogopoulos and in collaboration with Cancer Research Society ​

Contact: jennifer.gardner@affiliate.mcgill.ca

Sponsored by BC Cancer Agency and in collaboration with BC Cancer Foundation 

Contact: jlaskin@bccancer.bc.ca   

Sites in Toronto, Ontario and Halifax, Nova Scotia are currently open for recruitment. 

  • Instagram
  • Facebook
  • Twitter
logoImage.png
leaf-cihr-colour-en_edited.png

The Canadian Cholangiocarcinoma Collaborative (C3) is supported by a Canadian Cancer Society Breakthrough Team Grant in partnership with the Canadian Institutes of Health Research. The granting funds for C3 are managed by The Ottawa Hospital Research Institute, which serves as the lead institute for all collaborative operations.

© 2025 www.cholangio.ca. All rights reserved.

bottom of page